Colon cancer

60 Years of Survival Outcomes at the University of Texas MD Anderson Cancer Center

Volumn , Issue , 2012, Pages 77-84

  Eng, Cathy ^a   Lynch, Patrick ^a   Skibber, John ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84886569742     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5197-6_8     Document Type: Chapter

References (12)

1. American Cancer Society. Cancer facts and figures, 2011. Atlanta: American Cancer Society; 2011.
2. Gleisner AL, Choti MA, Assumpcao L, et al. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resectionradiofrequency ablation. Arch Surg. 2008;143:1204-12.
3. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609-18.
4. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of bene fit from fl uorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-57.
5. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:191-5.
6. Deng G, Peng E, Gum J, et al. Methylation of hMLH1 promoter correlates with the gene silencing with a region-speci fic manner in colorectal cancer. Br J Cancer. 2002;86:574-9.
7. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979-94.
8. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001;93:583-96.
9. West NP, Hohenberger W, Weber K, et al. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol. 2010;28:272-8.
10. Joseph NE, Sigurdson ER, Hanlon AL, et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol. 2003;10:213-8.
11. Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG intergroup phase III Trial N0147 [abstract CRA3507]. J Clin Oncol. 2010;28(Suppl):959s.
12. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol. 2011;29:11-6.